Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I–III patients treated with standard therapy
Maria Vittoria Dieci(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Federica Miglietta(University of Padua), Giulia Tasca(University of Padua), Vassilena Tsvetkova(University of Padua), Valentina Guarneri(Istituto Oncologico Veneto), Enrico Orvieto(AULSS 2 Marca Trevigiana), Marcello Mele(University of Pisa), Carlo Alberto Giorgi(Istituto Oncologico Veneto), Davide Massa(University of Padua), Gaia Griguolo(University of North Carolina at Chapel Hill), Enrico Cumerlato(University of Padua)
Cited by 74
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|983
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830